B

SCL사이언스

246960KOSDAQ

56.7 / 100

Reference Date: 2026-09-08

Financial Score11.0 / 40
News Sentiment20.7 / 25
Momentum13.0 / 20
Disclosure12.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Surged 31.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

SCL Science is a company specializing in protein-based platform technologies, offering hemostatic products, bio-logging services, and healthcare data platforms. In 2025, its consolidated sales reached 22,011 million KRW, reflecting a 365% increase driven by growth in bio-logging and data platform services. Key products include the 'InnoSEAL' hemostatic series, 'InTro' catheters, and AI-powered medical data solutions, with expansion into high-risk medical device markets and global bio-logging services.

Number of Employees

163people

Average Salary

77.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
3.24Industry Average 1.200.0Point

2.7x industry avg (risky)

ROE
-21.12Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
134.87Industry Average 100.002.0Point

Higher than industry avg (caution)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲311.5% (2-year basis)

Operating Profit Growth Rate
2.0 / 3

Avg ▲8.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -24.7% (improving, 3yr)

Detailed News Sentiment

16 totalPositive 15Neutral 1Negative 0Average Sentiment Score 82.8

Detailed Momentum

52-week position5.0Point

52w mid range (52%)

Current 2,240Won52-week high 2,97052-week low 1,440
1-month return6.0Point

1m +31.92% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-08-18
  • Neutral반기보고서 (2026.06)2026-08-14
  • Positive단일판매ㆍ공급계약체결2026-08-10